1. The Market Context: A $400 Billion Patent Cliff and What It Means for Generic Entrants Between 2025 and 2030, […]
The patent cliff is not a metaphor. It is a measurable revenue event. When a branded drug loses market exclusivity,
1. Why Late-Stage LCM Has Become a Board-Level Discipline The pharmaceutical industry is staring at its largest revenue destruction event
1. The Reverse Supply Chain: Scale, Scope, and Why It Landed on the CFO’s Desk The pharmaceutical forward supply chain
Executive Overview: The High-Stakes Architecture of Market Exclusivity The global pharmaceutical industry operates at the precarious intersection of intellectual property
A deep-dive reference for pharmaceutical IP teams, R&D leads, payer strategy groups, and institutional investors. Executive Summary The question of
I. Why Patent Strategy Is Really Business Strategy Here is a number worth sitting with: the U.S. pharmaceutical industry spent
Drug Patents: The Complete Playbook for Pharmaceutical Competitive Advantage Read Post »
Executive Lead: Why Emerging Markets Are the Only Game That Matters The global generic drug market will reach approximately USD
Generic Drug Entry in Emerging Markets: The $927B Patent Cliff Playbook Read Post »
Global Pharmaceutical Distribution and Patent Exclusivity: A Strategic Framework The global pharmaceutical market exceeds 1.48 trillion dollars in annual valuation.
Get fresh news and insights, drug patent expirations & more…
